Products for Research Use Only

Gemtuzumab

CAT: 0804-HY-P99971-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99971-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin. Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)[2].
CAS Number
220578-59-6
UNSPSC
12352203
Target
ADC Antibody; Transmembrane Glycoprotein
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/gemtuzumab.html
Purity
99.54
Solubility
10 mM in DMSO
Smiles
[Gemtuzumab]
Molecular Weight
(145.22 kDa)
References & Citations
[1]McGavin JK, et al. Gemtuzumab ozogamicin. Drugs. 2001;61 (9) :1317-22; discussion 1323-4. |[2]Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia. National Cancer Institute. 2017 Sept. |[3]Petrich, T., et al., (2010) . In vitro experimental (211) At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. European journal of nuclear medicine and molecular imaging, 37 (5), 851–861.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4